Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 5.4% during mid-day trading on Monday . The stock traded as high as $13.43 and last traded at $12.66. 861,005 shares traded hands during trading, a decline of 33% from the average session volume of 1,277,415 shares. The stock had previously closed at $12.01.

Several research firms have recently commented on CLDX. BidaskClub downgraded Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 15th. Zacks Investment Research cut Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 1st. ValuEngine upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald boosted their price objective on shares of Celldex Therapeutics from $12.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, July 1st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $15.67.

The stock has a market cap of $495.34 million, a price-to-earnings ratio of -4.56 and a beta of 3.16. The stock has a fifty day simple moving average of $11.16 and a two-hundred day simple moving average of $6.52.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.90 million. Celldex Therapeutics had a negative net margin of 1,035.16% and a negative return on equity of 36.44%. On average, equities analysts forecast that Celldex Therapeutics, Inc. will post -1.83 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC grew its position in Celldex Therapeutics by 20.4% during the 1st quarter. Acadian Asset Management LLC now owns 298,649 shares of the biopharmaceutical company’s stock worth $496,000 after acquiring an additional 50,583 shares during the last quarter. Creative Planning raised its stake in shares of Celldex Therapeutics by 191.0% during the second quarter. Creative Planning now owns 35,347 shares of the biopharmaceutical company’s stock valued at $460,000 after acquiring an additional 23,200 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Celldex Therapeutics by 61.3% during the second quarter. WINTON GROUP Ltd now owns 19,401 shares of the biopharmaceutical company’s stock valued at $252,000 after acquiring an additional 7,374 shares during the last quarter. Mirador Capital Partners LP grew its stake in shares of Celldex Therapeutics by 68.8% in the second quarter. Mirador Capital Partners LP now owns 19,134 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 7,802 shares during the last quarter. Finally, Monashee Investment Management LLC acquired a new stake in Celldex Therapeutics in the second quarter valued at $3,900,000. 70.89% of the stock is currently owned by institutional investors.

Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

See Also: Why do analysts give a neutral rating?

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.